Clopidogrel hydrogen sulfate

Research use only, not for human use.

A thienopyridine-class antiplatelet agent that works by irreversibly inhibiting P2Y12 receptor on platelets.

A thienopyridine-class antiplatelet agent that works by irreversibly inhibiting P2Y12 receptor on platelets; used to reduce the risk of heart disease and stroke in those at high risk.Thrombosis Approved(In Vitro):Clopidogrel (1.5 mM;12 and 24 hours) up-regulates the expression of TRIB3 and CHOP in a concentration- and time-dependent manner, as measured by real-time PCR and Western blot analysis.Clopidogrel (1.5 mM; 24 hours) significantly induces human gastric epithelial cell (GES-1) apoptosis.(In Vivo):Clopidogrel (5 mg/kg) significantly inhibits thrombus formation compared with vehicle. Acetylsalicylic acid (0.15 mg/kg) can add to the antithrombotic effect of Clopidogrel in mice; Acetylsalicylic acid (0.6 mg/kg) blunts the antithrombotic effect of Clopidogrel.

——

Animal Model:Age-matched C57BL/6J male mice weighing at least 25 g were used at 8 to 12 weeks of ageDosage:5 mg/kgAdministration:Gavage treatmentResult:Clopidogrel significantly inhibited thrombus formation compared with vehicle.When Clopidogrel was given in combination with 0.6 mg/kg ASA, thrombi were significantly larger than those measured with Clopidogrel alone. In contrast, when Clopidogrel was given in combination with 0.15 mg/kg ASA , thrombi were significantly smaller than those in mice treated with Clopidogrel and 0.6 mg/kg ASA, and smaller than those in mice given Clopidogrel alone.

S)-(+)-Clopidogrel bisulfate

GPCR/G Protein

P2Y Receptor

P2Y

Cardiovascular Disease

Thrombosis

120202-66-6

419.9002

C16H18ClNO6S2

>98% (HPLC)

DMSO: ≥ 46.7 mg/mL

OS(O)(=O)=O.COC(=O)CN1CCC2=C(C1)C=C(S2)C1=CC=CC=C1Cl

Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)-, sulfate (1:1)

(-20℃)

With Ice Pack

≥ 2 years